Long term safety of nine systemic medications for psoriasis: a cohort study using the Biobadaderm Registry.

Like Comment
Registry studies broadly describing the safety of systemic drugs in psoriasis are needed.To describe the safety findings of systemic drugs (acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, ustekinumab) used for the treatment of moderate-to-severe psoriasis in patients included in Biobadaderm.The incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events (AE) for each drug, using methotrexate as reference, were determined by means of a prospective cohort.Our study included 2,845 patients (8,954 treatment cycles; 9,642 patient-years). Ustekinumab and secukinumab had the lowest rate of adverse events for several of the system organ class with statistically significant decreased rate ratio (IRR<1), whereas cyclosporine and infliximab had the highest, with increased rate ratio (IRR = 5).Observational study, drug allocation not randomized, depletion of susceptibles, prescribed doses not registered.Our data provide comparative safety information in the real-life setting that could help clinicians selecting between available products.

Click here to read the full article @ Journal of the American Academy of Dermatology


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6577 Contributions
0 Following